[Midazolam (Dormicum) in terminal anxiety and agitation. The last choice alternative in palliative care].
Although midazolam has been proposed for the treatment of a variety of conditions such as anxiety, dyspnoea, hiccups and status epilepticus, terminal agitation is the only condition where its use is based on a reasonably large number of published clinical studies. A causal approach is generally recommended. Whenever possible, the aetiological condition (pain, fever, constipation, etc.) should be corrected. Such general measures as ensuring a peaceful, familiar environment, and the use of a night light, fluid therapy to counteract dehydration, and antipyretics for fever are beneficial. When symptomatic treatment is needed, drugs with little anticholinergic effect are to be recommended. The use of benzodiazepines as single drug treatment may exacerbate the condition. Haloperidol or risperidone (which has fewer side effects) are recommended. If the agitation is marked, a common strategy is to add lorazepam. Chlormethiazole is an alternative. Subcutaneous midazolam should be reserved for refractory cases. Attention should be paid to dosage, reduced doses being given to the elderly, patients on opioid medication, and patients with impaired liver or renal function. Overdosage may induce deep sedation, and result in carbon dioxide retention and subsequently heart failure and pulmonary oedema which may be fatal.
Jakobsson
M
M
Universitetet i Linköping, Vrinnevisjukhuset, Norrköping.
Strang
P
P
D014151:Anti-Anxiety Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D001008:Anxiety Disorders / Q000188:drug therapy*; D006801:Humans; D008874:Midazolam / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D010166:Palliative Care; D011595:Psychomotor Agitation / Q000188:drug therapy*; D013727:Terminal Care
D014151:Anti-Anxiety Agents; D008874:Midazolam